Proteomics for the early diagnosis and treatment of hepatocellular carcinoma

摘要: The incidence of primary cancer has been increasing globally and now-a-days it constitutes the 5th most frequent humans representing around 5% all cancers worldwide. Chronic HBV infection assumes greater significance because its reported association with cirrhosis, more ominously hepatocellular carcinoma or HCC. Hepatitis B a major global problem nearly 400 million infected individuals. It contributes to significant degree morbidity on account associated chronicity that develops in 5-10% adults than 90% neonates. Globally, one people suffering from HBVrelated chronic heptatitis HCC die per year. Despite availability an effective prophylactic vaccine against hepatitis for over 20 years, treatment disease remains elusive. Therefore, identification cellular mediators effectors is important medical objective developing new diagnostic tools therapeutic strategies it. Molecular biomarkers hold great promise refining our ability establish early diagnosis prognosis HCC, predict response therapy. Proteomics rapidly expanding discipline expected change way which can be diagnosed, treated monitored near future. proteomic analysis serum tumors should allow accurate prediction what happening at protein level cell body fluid proteome.